Loss of histone H2AX increases sensitivity of immortalized mouse fibroblasts to the topoisomerase II inhibitor etoposide

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 613-621

  Donà, Francesca ^a   Prosperi, Ennio ^a   Savio, Monica ^b   Coppa, Tania ^b   Scovassi, Ivana A ^a   Mondello, Chiara ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cell cycle; Comet assay; H2AX etoposide; Micronuclei; Mitotic death

Indexed keywords

CYCLIN A; CYCLIN B1; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; ETOPOSIDE; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; ANTINEOPLASTIC AGENT; CYCLIN B; DNA TOPOISOMERASE (ATP HYDROLYSING); H2AX PROTEIN, MOUSE; HISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADP RIBOSE)POLYMERASE 1, MOUSE; POLY(ADP-RIBOSE)POLYMERASE-1, MOUSE;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL IMMORTALIZATION; CELL NUCLEUS; CLONOGENIC ASSAY; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG SENSITIVITY; EMBRYO; FIBROBLAST; FLOW CYTOMETRY; GENE LOSS; GENETIC STABILITY; KNOCKOUT MOUSE; MAMMAL CELL; MICRONUCLEUS; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WILD TYPE; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; COMET ASSAY; CYCLIN A; CYCLIN B; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FIBROBLASTS; FLOW CYTOMETRY; HISTONES; MICE; MICE, KNOCKOUT; POLY(ADP-RIBOSE) POLYMERASES;

EID: 54849186100     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000047     Document Type: Article

References (31)

1. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998.
2. Redon C, Pilch DR, Rogakou EP, Orr AH, Lowndes NF and Bonner WM: Yeast histone 2A serine 129 is essential for the efficient repair of check-point-blind DNA damage. EMBO Rep 4: 678-684, 2003.
3. Downs JA, Nussenzweig MC and Nussenzweig A: Chromatin dynamics and the preservation of genetic information. Nature 447: 951-958, 2007.
4. Fernandez-Capetillo O, Lee A, Nussenzweig M and Nussenzweig A: H2AX: the histone guardian of the genome. DNA Repair 3: 959-967, 2004.
5. Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, Sedelnikova OA, Reina-San-Martin B, Coppola V, Meffre E, Difilippantonio MJ, Redon C, Pilch DR, Olaru A, Eckhaus M, Camerini-Otero RD, Tessarollo L, Livak F, Manova K, Bonner WM, Nussenzweig MC and Nussenzweig A: Genomic instability in mice lacking histone H2AX. Science 296: 922-927, 2002.
6. Bassing CH, Chua KF, Sekiguchi J, Suh H, Whitlow SR, Fleming JC, Monroe BC, Ciccone DN, Yan C, Vlasakova K, Livingston DM, Ferguson DO, Scully R and Alt FW: Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci USA 99: 8173-8178, 2002.
7. Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanienko PJ, Morales JC, Naka K, Xia Z, Camerini-Otero RD, Motoyama N, Carpenter PB, Bonner WM, Chen J and Nussenzweig A: DNA damage-induced G2-M check-point activation by histone H2AX and 53BP1. Nat Cell Biol 4: 993-997, 2002.
8. Franco S, Gostissa M, Zha S, Lombard DB, Murphy MM, Zarrin AA, Yan C, Tepsuporn S, Morales JC, Adams MM, Lou Z, Bassing CH, Manis JP, Chen J, Carpenter PB and Alt FW: H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell 21: 201-214, 2006.
9. Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3: 430-440, 2002.
10. Montecucco A and Biamonti G: Cellular response to etoposide treatment. Cancer Lett 252: 9-18, 2007.
11. Adachi N, Suzuki H, Iiizunii S and Koyama H: Hypersensitivity of non-homologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem 278: 35897-35902, 2003.
12. Adachi N, Iiizumi S, So S and Koyama H: Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage. Biochem Biophys Res Commun 318: 856-861, 2004.
13. Kantidze OL, Iarovaia OV and Razin SV: Assembly of nuclear matrix-bound protein complexes involved in non-homologous end joining is induced by inhibition of DNA topoisomerase II. J Cell Physiol 207: 660-667, 2006.
14. Kantidze OL and Razin SV: Chemotherapy-related secondary leukemias: a role for DNA repair by error-prone non-homologous end joining in topoisomerase II-induced chromosomal rearrangements. Gene 391: 76-79, 2007.
15. Negri C, Bernardi R, Donzelli M and Scovassi AI: Induction of apoptotic cell death by DNA topoisomerase II inhibitors. Biochimie 77: 893-899, 1995.
16. Baldwin EL and Osheroff N: Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5: 363-372, 2005.
17. Sherr CJ and De Pinho RA: Cellular senescence: mitotic clock or culture shock? Cell 102: 407-410, 2000.
18. Collins AR: The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26: 249-261, 2004.
19. Soldani C and Scovassi AI: Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7: 321-328, 2002.
20. Donzelli M, Bernardi R, Negri C, Prosperi E, Padovan L, Lavialle C, Brison O and Scovassi AI: Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene. Oncogene 18: 439-448, 1999.
21. Woo RA and Poon RY: Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle 2: 316-324, 2003.
22. Chang DC, Xu N and Luo KQ: Degradation of cyclin B is required for the onset of anaphase in mammalian cells. J Biol Chem 278: 37865-37873, 2003.
23. Bassermann F, Peschel C and Duyster J: Mitotic entry: a matter of oscillating destruction. Cell Cycle 4: 1515-1517, 2005.
24. Muller WU, Nusse M, Miller BM, Slavotinek A, Viaggi S and Streffer C: Micronuclei: a biological indicator of radiation damage. Mutat Res 366: 163-169, 1996.
25. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2925-2837, 2004.
26. Tounekti O, Pron G, Belehradek J Jr and Mir LM: Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 53: 5462-5469, 1993.
27. Mackey MA and Ianzini F: Enhancement of radiation-induced mitotic catastrophe by moderate hyperthermia. Int J Radiat Biol 76: 273-280, 2000.
28. Ianzini F, Bertoldo A, Kosmacek EA, Phillips SL and Mackey MA: Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells. Cancer Cell Int 6: 11, 2006.
29. Lock RB, Galperina OV, Feldhoff RC and Rhodes LJ: Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res 54: 4933-4939, 1994.
30. Yoshida K and Morita T: Control of radiosensitivity of F9 mouse teratocarcinoma cells by regulation of histone H2AX gene expression using a tetracycline turn-off system. Cancer Res 64: 4131-4136, 2004.
31. Kao J, Milano MT, Javaheri A, Garofalo MC, Chmura SJ, Weichselbaum RR and Kron SJ: gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets 6: 197-205, 2006.